Mood Disorders

Psychopharmacology

Neurobiologic Insights into Major Depressive Disorder: An Update on Emerging Therapies with Novel Mechanisms of Action

Thursday, October 25
3:45 PM - 5:00 PM
Location: Tangerine WF1

Recent insights into the pathophysiology of major depressive disorder have led to the discovery of novel therapeutic targets that offer new hope for patients with treatment-resistant depression, including the modulation of glutamatergic, GABAergic, or cholinergic neurotransmitter signaling; regulation of neuronal plasticity; alterations in the stress/hypothalamic-pituitary-adrenal axis and neuroinflammation; and mediation of opioid signaling pathways. In this session, Dr. Thase will lead a high-level review of the potential role of these new treatment targets and medications in the current treatment armamentarium.

Supported by an educational grant from Alkermes, Inc.

Michael E. Thase, MD

Professor of Psychiatry
Perelman School of Medicine at the University of Pennsylvania, Philadelphia Veterans Affairs Medical Center
Perelman School of Medicine at the University of Pennsylvania SOM
Media, PA

Michael E. Thase, MD, joined the faculty of the Perelman School of Medicine at the University of Pennsylvania School of Medicine in January 2007 as Professor of Psychiatry and director of the Department of Psychiatry’s Mood and Anxiety Section after more than 27 years at the University of Pittsburgh. A 1979 graduate of the Ohio State University College of Medicine, Dr. Thase is a Distinguished Fellow of the American Psychiatric Association, a Founding Fellow of the Academy of Cognitive Therapy, President of the American Society of Clinical Psychopharmacology, and Vice Chairman of the Scientific Advisory Board of the National Depression and Bipolar Support Alliance. Dr. Thase has been elected to the membership of the American College of Psychiatrists and the American College of Neuropsychopharmacology. Dr. Thase’s research, which has been continuously funded by the Institutes of the NIH for nearly 30 years, focuses on the assessment and treatment of mood disorders, including studies of the differential therapeutics of both depression and bipolar affective disorder. Recent research projects have included studies of novel ketamine-like compounds, a multicenter study of the efficacy of rTMS for depressed veterans, a multicenter trial comparing the effectiveness and tolerability of lithium and quetiapine for bipolar depression and a large scale noninferiority trial comparing a novel computer-administered form of Cognitive Therapy versus the conventional 20 session/16-week model of treatment. Dr. Thase has authored or co-authored more than 700 scientific articles and book chapters, as well as 16 books.

Presentation(s):

Send Email for Michael Thase


Assets

Neurobiologic Insights into Major Depressive Disorder: An Update on Emerging Therapies with Novel Mechanisms of Action



Attendees who have favorited this

Please enter your access key

The asset you are trying to access is locked. Please enter your access key to unlock.

Send Email for Neurobiologic Insights into Major Depressive Disorder: An Update on Emerging Therapies with Novel Mechanisms of Action